Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure

被引：34

作者：

Jaglal, Michael V. ^{[1
]}

Duong, Vu H. ^{[2
]}

Bello, Celeste M. ^{[1
]}

Al Ali, Najla H. ^{[1
]}

Padron, Eric ^{[1
]}

Fernandez, Hugo F. ^{[1
]}

List, Alan F. ^{[1
]}

Lancet, Jeffrey E. ^{[1
]}

Komrokji, Rami S. ^{[1
]}

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA

[2] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

来源：

LEUKEMIA RESEARCH | 2014年 / 38卷 / 04期

关键词：

Azanucleoside treatment failure; Antecedent hematological disorders; Cladrabine; Secondary AML; ACUTE MYELOGENOUS LEUKEMIA; INTENSIVE CHEMOTHERAPY; RISK; OUTCOMES; THERAPY; MULTICENTER; ARABINOSIDE; EFFICACY; ANALOGS; AML;

D O I：

10.1016/j.leukres.2013.12.010

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3 + 7 induction chemotherapy (24 patients). Response rates (p= 0.014) and median overall survival (p= 0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3 + 7 cohorts, respectively. Median overall survival was 202 (95% CI 37-367 days) versus 86 days (95% CI 36-136) (p= 0.025), respectively. CLAG-M has encouraging activity in this patient group. (c) 2013 Elsevier Ltd. All rights reserved.

引用

页码：443 / 446

页数：4

共 23 条

[1] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[2] In AML cell lines Ara-C combined with purine analogues is able to exert synergistic as well as antagonistic effects on proliferation, apoptosis and disruption of mitochondrial membrane potential [J].

Chow, KU ;

Boehrer, S ;

Napieralski, S ;

Nowak, D ;

Knau, A ;

Hoelzer, D ;

Mitrou, PS ;

Weidmann, E .

LEUKEMIA & LYMPHOMA, 2003, 44 (01) :165-173

[3] Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study [J].

Fenaux, Pierre ;

Mufti, Ghulam J. ;

Hellstrom-Lindberg, Eva ;

Santini, Valeria ;

Finelli, Carlo ;

Giagounidis, Aristoteles ;

Schoch, Robert ;

Gattermann, Norbert ;

Sanz, Guillermo ;

List, Alan ;

Gore, Steven D. ;

Seymour, John F. ;

Bennett, John M. ;

Byrd, John ;

Backstrom, Jay ;

Zimmerman, Linda ;

McKenzie, David ;

Beach, C. L. ;

Silverman, Lewis R. .

LANCET ONCOLOGY, 2009, 10 (03) :223-232

[4] Anthracycline Dose Intensification in Acute Myeloid Leukemia [J].

Fernandez, Hugo F. ;

Sun, Zhuoxin ;

Yao, Xiaopan ;

Litzow, Mark R. ;

Luger, Selina M. ;

Paietta, Elisabeth M. ;

Racevskis, Janis ;

Dewald, Gordon W. ;

Ketterling, Rhett P. ;

Bennett, John M. ;

Rowe, Jacob M. ;

Lazarus, Hillard M. ;

Tallman, Martin S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (13) :1249-1259

[5] Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia [J].

Font P. .

Advances in Therapy, 2011, 28 (Suppl 3) :1-9

[6] EFFICACY OF INTENSIVE CHEMOTHERAPY FOR ACUTE MYELOGENOUS LEUKEMIA ASSOCIATED WITH A PRELEUKEMIC SYNDROME [J].

GAJEWSKI, JL ;

HO, WG ;

NIMER, SD ;

HIRJI, KF ;

GEKELMAN, L ;

JACOBS, AD ;

CHAMPLIN, RE .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1637-1645

[7] Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: Pharmacokinetic, pharmacodynamic, and molecular interactions [J].

Gandhi, V ;

Estey, E ;

Keating, MJ ;

Chucrallah, A ;

Plunkett, W .

BLOOD, 1996, 87 (01) :256-264

[8] CELL CYCLE-SPECIFIC METABOLISM OF ARABINOSYL NUCLEOSIDES IN K562 HUMAN LEUKEMIA-CELLS [J].

GANDHI, V ;

PLUNKETT, W .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 31 (01) :11-17

[9] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

[10] Cladribine, But Not Fludarabine, Added to Daunorubicin and Cytarabine During Induction Prolongs Survival of Patients With Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Study [J].

Holowiecki, Jerzy ;

Grosicki, Sebastian ;

Giebel, Sebastian ;

Robak, Tadeusz ;

Kyrcz-Krzemien, Slawomira ;

Kuliczkowski, Kazimierz ;

Skotnicki, Aleksander B. ;

Hellmann, Andrzej ;

Sulek, Kazimierz ;

Dmoszynska, Anna ;

Kloczko, Janusz ;

Jedrzejczak, Wieslaw W. ;

Zdziarska, Barbara ;

Warzocha, Krzysztof ;

Zawilska, Krystyna ;

Komarnicki, Mieczyslaw ;

Kielbinski, Marek ;

Piatkowska-Jakubas, Beata ;

Wierzbowska, Agnieszka ;

Wach, Malgorzata ;

Haus, Olga .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2441-2448

← 1 2 3 →